Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility

International Clinical Psychopharmacology

Volumn 22, Issue 6, 2007, Pages 356-362

  Citrome, Leslie ^a,b   Shope, Constance B ^a   Nolan, Karen A ^a,b   Czobor, Pal ^a,c   Volavka, Jan ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DOV Pharmaceutical Inc   (United States)

Author keywords

Aggression; Hostility; Impulsivity; Risperidone; Schizophrenia; Valproate

Indexed keywords

BENZATROPINE; LORAZEPAM; RISPERIDONE; VALPROATE SEMISODIUM;

ADULT; ARTICLE; BARRATT IMPULSIVENESS SCALE; BUSS DURKEE HOSTILITY INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; ECG ABNORMALITY; FEMALE; FROZEN SHOULDER; GASTROINTESTINAL SYMPTOM; HOSTILITY; HUMAN; JAW DISEASE; LEUKOCYTE COUNT; MALE; MENTAL PATIENT; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NURSE OBSERVATION SCALE FOR INPATIENT EVALUATION; OVERT AGGRESSION SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; THERAPY EFFECT; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VOMITING; XEROSTOMIA;

ADULT; AGGRESSION; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; DIARRHEA; DRUG THERAPY, COMBINATION; FEMALE; HOSTILITY; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NAUSEA; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME; VALPROIC ACID; VOMITING;

EID: 34948856375     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3281c61baf     Document Type: Article

References (30)

1. Abbott Laboratories (2006). ABT-711 M02-547 Clinical Study Report. Available at: http://www.clinicalstudyresults.org/documents/companystudy_ 782_0.pdf. Accessed March 20, 2007.
2. Barratt ES, Stanford MS (1995). Impulsiveness. In: Costello CG, editor. Personality characteristics of the personality disordered client. New York: Wiley. pp. 91-118.
3. Bowden CL (2007). Spectrum of effectiveness of valproate in neuropsychiatry. Exp Rev Neurother 7:9-16.
4. Buss AH, Durkee A (1957). An inventory for assessing different kinds of hostility. J Consult Psychol 21:343-349.
5. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW (2003). Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28: 182-192.
6. Chengappa KN, Goldstein JM, Greenwood M, John V, Levine J (2003). A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 25:530-541.
7. Chouinard G, Margolese HC (2005). Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76:247-265.
8. Citrome L (1995). Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. J Pharm Technol 11:55-59.
9. Citrome L (2003). Schizophrenia and valproate. Psychopharmacol Bull 37 (Suppl 2):74-88.
10. Citrome L (2004). Treatment-resistant schizophrenia: what role for mood stabilizers? Curr Psychiatry 3:23-26, 32-34, 39-40. Available at: http:// www.currentpsychiatry.com/pdf/0312/0312_Article2.pdf. Accessed March 20, 2007.
11. Citrome L, Levine J, Allingham B (2000). Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 51:634-638.
12. Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, et al. (2001). Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 52: 1510-1514.
13. Citrome L, Jaffe A, Levine J (2002). Datapoints-mood stabilizers: utilization trends in patients diagnosed with schizophrenia 1994-2001. Psychiatr Serv 53:1212.
14. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA (2004). Effects of adjunctive valproate on hostility in patients with schizophrenia receiving olanzapine or risperidone: a double-blind multi-center study. Psychiatr Serv 55:290-294.
15. Citrome L, Nolan KA, Volavka J (2004). Science-based treatment of aggression and agitation. In: Fishbein D, editor. The science, treatment, and prevention of antisocial behaviors: evidence-based practice. Volume 2. Kingston, NJ: Civic Research Institute, Inc. pp. 11.1-11.31.
16. Citrome L, Jaffe A, Levine J (2005). Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol 25: 388-391.
17. Citrome L, Volavka J, Czobor P, Brook S, Loebel A, Mandel FS (2006). Efficacy of ziprasidone against hostility in schizophrenia. J Clin Psychiatry 67:638-642.
18. Czobor P, Volavka J, Meibach RC (1995). Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 15:243-249.
19. Guy W (1976). ECDEU Assessment manual for psychopharmacology, Revised 1976. Rockville, Maryland: US Department of Health, Education, and Welfare.
20. Honigfeld G (1974). Nosie-30: history and current status of its use in pharmacopsychiatric research. Mod Probl Pharmacopsychiatry 7:238-263.
21. Honigfeld G, Gillis RD, Klett CJ (1966). Nosie-30: a treatment-sensitive ward behavior scale. Psychol Rep 19:180-182.
22. Kay SR, Opler LA, Lindenmayer JP (1989). The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry (Suppl) 155:59-65.
23. Kinon BJ, Liu-Seifert H, Adams DH, Citrome L (2006). Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J Clin Psychopharmacol 26:632-637.
24. Krakowski MI, Czobor P, Citrome L, Bark N, Cooper T (2006). Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 63:622-629.
25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
26. Nolan KA, Volavka J (2006). Video recording in the assessment of violent incidents in psychiatric hospitals. J Psychiatr Pract 12:58-63.
27. Silver JM, Yudofsky SC (1991). The Overt Aggression Scale: overview and guiding principles. J Neuropsychiatry Clin Neurosci 3:S22-S29.
28. Volavka J, Citrome L (1999). Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr Res 35:S23-S33.
29. Volavka J, Czobor P, Citrome L, McQuade RD, Carson WH, Kostic D, et al. (2005). Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder. J Clin Psychiatry 66:1362-1366.
30. White L, Harvey PD, Opler L, Lindenmayer JP (1997). Empirical Assessment of the Factorial Structure of Clinical Symptoms in Schizophrenia. Psychopathology 30:263-274.